Murat Kara1, Özgür Kara2, Yasin Ceran3, Bayram Kaymak1, Tuğçe Cansu Kaya2, Beyza Nur Çitir2, Mahmut Esad Durmuş2, Esra Durmuşoğlu2, Sarah Razaq4, Yahya Doğan5, Dia Shehab6, Salem A Alkandari7, Ahmad J Abdulsalam6, Ayşe Merve Ata8, Esra Gizem Koyuncu1, Evrim Coşkun9, Gökhan Turan2, Banu Dilek10, Mehmet Ali Culha11, Pelin Yildirim12, Kamal Mezian13, Beril Doğu14, Gamze Kiliç15, Zeliha Ünlü16, Jorge Barbosa17, Sérgio Pinho17, Pelin Analay1, Deniz Palamar18, Orhan Güvener19, Hasan Ocak1, Fevziye Ünsal Malas8, Murat Baday20, Banu Çakir21, Levent Özçakar1. 1. Hacettepe University Medical School, Department of Physical and Rehabilitation Medicine, Ankara, Turkey. 2. Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Department of Internal Medicine, Ankara, Turkey. 3. Department of Business and Technology Management, Korea Advanced Institute of Science and Technology, Seoul, South Korea. 4. Combined Military Hospital & Quetta Institute of Medical Sciences, Quetta, Pakistan. 5. Hacettepe University, Faculty of Physical Therapy and Rehabilitation, Ankara, Turkey. 6. Physical Medicine and Rehabilitation Hospital, Andalous, Kuwait. 7. Department of Physical Medicine and Rehabilitation, Physical Medicine and Rehabilitation Hospital, Andalous, Kuwait. 8. Ankara City Hospital, Department of Physical Medicine and Rehabilitation, Ankara, Turkey. 9. University of Health Science, Basaksehir Cam and Sakura City Hospital, Department of Physical Medicine and Rehabilitation, İstanbul, Turkey. 10. Dokuz Eylül University Medical School, Department of Physical and Rehabilitation Medicine, İzmir, Turkey. 11. Kozan State Hospital, Department of Physical and Rehabilitation Medicine, Adana, Turkey. 12. Kocaeli Derince Training and Research Hospital, Department of Physical Medicine and Rehabilitation, Kocaeli, Turkey. 13. Charles University and General University Hospital, Prague, Czech Republic. 14. University of Health Sciences, Sisli Hamidiye Etfal Teaching and Research Hospital, Department of Physical Medicine and Rehabilitation, Istanbul, Turkey. 15. Karadeniz Technical University Faculty of Medicine, Department of Physical and Rehabilitation Medicine, Trabzon, Turkey. 16. Celal Bayar University, Department of Physical Medicine and Rehabilitation, Manisa, Turkey. 17. Centro Hospitalar de Lisboa Ocidental, Department of Physical Medicine and Rehabilitation, Lisbon, Portugal. 18. İstanbul University-Cerrahpaşa Cerrahpaşa School of Medicine, Department of Physical Medicine and Rehabilitation, İstanbul, Turkey. 19. Mersin University Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Mersin, Turkey. 20. Stanford University, Department of Neurology. 21. Hacettepe University Medical School, Department of Public Health, Division of Epidemiology, Ankara, Turkey.
Abstract
OBJECTIVE: To investigate the relationship between sarcopenia and RAS-related disorders and to explore the effects of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin-II receptor blockers (ARBs) on muscle mass/function and physical performance. DESIGN: This multi-center, cross-sectional study was performed using ISarcoPRM algorithm for the diagnosis of sarcopenia. RESULTS: Of the 2613 participants (mean age; 61.0 ± 9.5 years), 1775 (67.9%) were hypertensive. All sarcopenia-related parameters [except chair stand test (CST) in males] were worse in hypertensive group than in normotensive group (all p < 0.05). When clinical/potential confounders were adjusted; HT was found to be an independent predictor of sarcopenia in males [OR = 2.403 (95%CI: 1.514-3.813)] and females [OR = 1.906 (95%CI: 1.328-2.734)] (both p < 0.001). After adjusting for confounding factors, we found that all sarcopenia-related parameters (except grip strength and CST in males) were independently/negatively related with HT (all p < 0.05). In females, ACEIs users had higher grip strength and CST performance values but had lower muscle thickness and gait speed values, as compared to those using ARBs (all p < 0.05). CONCLUSIONS: Hypertension was associated with increased risk of sarcopenia at least two times. Among antihypertensives; while ACEIs had higher muscle values, ARBs had higher muscle mass and physical performance values only in females.
OBJECTIVE: To investigate the relationship between sarcopenia and RAS-related disorders and to explore the effects of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin-II receptor blockers (ARBs) on muscle mass/function and physical performance. DESIGN: This multi-center, cross-sectional study was performed using ISarcoPRM algorithm for the diagnosis of sarcopenia. RESULTS: Of the 2613 participants (mean age; 61.0 ± 9.5 years), 1775 (67.9%) were hypertensive. All sarcopenia-related parameters [except chair stand test (CST) in males] were worse in hypertensive group than in normotensive group (all p < 0.05). When clinical/potential confounders were adjusted; HT was found to be an independent predictor of sarcopenia in males [OR = 2.403 (95%CI: 1.514-3.813)] and females [OR = 1.906 (95%CI: 1.328-2.734)] (both p < 0.001). After adjusting for confounding factors, we found that all sarcopenia-related parameters (except grip strength and CST in males) were independently/negatively related with HT (all p < 0.05). In females, ACEIs users had higher grip strength and CST performance values but had lower muscle thickness and gait speed values, as compared to those using ARBs (all p < 0.05). CONCLUSIONS: Hypertension was associated with increased risk of sarcopenia at least two times. Among antihypertensives; while ACEIs had higher muscle values, ARBs had higher muscle mass and physical performance values only in females.